Kornimate/medical-research-clean huggingface dataset:
cartoon: coronavirus (covid-19) educational program for children

Conditions: Covid19; Pediatric Psychiatric Disorder; Psychological Stress

Summary: our study aims to investigate whether our coronavirus educational program for children (cartoon) facilitates the adherence to hygiene measures and is feasible to dispel fear in preschool children (3-6 years old) during the pandemic.

this prospective randomized controlled trial will be performed at four kindergartens in vienna, austria. about 60 children between three and six years of age attending kindergarten will be included in the study. prior inclusion in the study eligible adults have to sign a parental consent form. we will randomly assign 30 children to the intervention group (n=30) and 30 children to the control group (n=30). depending on the randomization (intervention group vs. control group), children either receive our cartoon (intervention group) or no educational training (control group).

Eligibility criteria:
inclusion criteria: * children between three and six years who are attending kindergarten * consent of the parents and the participants exclusion criteria: * physically unable to complete any of the training exercises * german skills not good enough to follow the instructions

Keywords: educational program education
efficacy of three novel bi-treated long lasting insecticidal nets

Conditions: Malaria; Anaemia

Summary: the massive scale-up of long lasting insecticidal nets (llin) has led to a major reduction in malaria burden (up to 50%) in many sub-saharan african countries. this progress is threatened by the wide scale selection of insecticide resistant malaria vectors. new types of llin combining a mixture of two insecticides or an insecticide and a synergist have been developed to control resistant mosquitoes. the efficacy of three bi-treated llin are compared to a standard llin in a four-arm, single blinded, cluster-randomized trial in misungwi district, tanzania. the arms are; 1/ royal guard, a net combining pyriproxyfen (ppf), which is known to disrupt female reproduction and fertility of eggs, and the pyrethroid alpha-cypermethrin, 2/interceptor g2, llin incorporating a mixture of two adulticides with different modes of action; chlorfenapyr and a pyrethroid (alpha-cypermethrin), and 3/ olyset plus an llin which incorporates a synergist, piperonyl butoxide (pbo), to enhance the potency of pyrethroid insecticides, and 4/ the control arm: interceptor treated a standard llin treated with alpha-cypermethrin. the primary outcome of the trial will be cross-sectional community prevalence of malaria infection (by rdt) in children aged 6 months to 14 years at 12 and 24 months post-intervention.


Eligibility criteria:
inclusion criteria: * at least one child between 6 months to 14 years old having permanent residence in selected household * having an adult caregiver willing to provide written consent for the household and clinical survey exclusion criteria: * dwelling not found or vacant during the survey * no adult caregiver capable to give informed consent * children severely ill

Keywords: malaria vector control long lasting insecticidal net
pelvic floor support after laparoscopic hysterectomy for benign conditions: a randomized controlled trial comparing vaginal cuff closure techniques

Conditions: Pelvic Organ Prolapse

Summary: the purpose of this study is to learn about the effect of different vaginal cuff closure techniques on pelvic support after laparoscopic hysterectomy and robotic assisted laparoscopic hysterectomy for benign gynecologic conditions.


Eligibility criteria:
inclusion criteria: * women over 18 years of age undergoing total laparoscopic hysterectomy and robotic assisted total laparoscopic hysterectomy for benign disease. * subjects must be able to self-consent. * department of defense beneficiary exclusion criteria: * patients will be excluded if they undergo a concurrent procedure for prolapse. * if the indication for the procedure is a malignancy. * those that plan to leave the area in less than 1 year will not be included. * pop-q point c of \>-4
airway microbiota based treatment of asthma in preschool children

Conditions: Asthma in Children

Summary: airway microbiota pattern may related the preschool asthma exacerbation. this is a single-center, randomized-controlled trial, the study will compare the management of preschool wheeze determined by airway microbiota phenotype and blood eosinophils level to the management using current clinical guidelines.

in this study, participants will be children aged 1-5 years who have recurrent wheezing and will be allocated to one of two treatment groups, either current clinical care or airway microbiota and blood eosinophils phenotype based management for 3 months.they will be followed up for one year after the intervention. the primary outcome is the frequency of unscheduled healthcare visit for wheezing, the secondary outcome parameters are events of severe wheezing requiring oral or intravenous steroids, events of emergency department visit and hospital admissions, the changes of test for respiratory and asthma control in kids (track) score and paediatric asthma caregiver's quality of life questionnaire (pacqlq) score.

Eligibility criteria:
inclusion criteria: * physician diagnosed recurrent wheeze（at least 3 episodes of wheezing or at least one course of oral steroids in the last 6 months） exclusion criteria: * any congenital heart disease diagnosed by a physician * any chronic respiratory condition other than preschool wheeze (bronchopulmonary dysplasia, bronchiolitis obliteran, congenital airway and lung malformations, bronchomalacia, chronic aspiration) diagnosed by a physician * received antibiotic last 6 weeks

Keywords: preschool wheeze airway microbiota
afri childhood obesity prevention challenge area

Conditions: Clinical Trial

Summary: this study is a hybrid type 2 effectiveness-implementation trial of the family check-up 4 health (fcu4health), an adapted version of the family check-up, in pediatric primary care. patients will be recruited based on their age (2-5 years old) and randomized to receive the intervention, fcu4health, or services as usual. all families will be assessed annually over three years.

the fcu4health is an assessment-driven, motivational interviewing (mi) based, parent training program. parents complete a comprehensive assessment, including questionnaire of the family environment, parenting skills, and child adjustment and health behaviors, and additional observation data. the fcu4health coordinator reviews the assessment results with the parents, using mi strategies to engage families in making change to support child behavioral health, and to create tailored follow-up services which include parent training modules and referrals to additional support services in the community.

Eligibility criteria:
inclusion criteria: * participating caregiver who is at least 18 years of age and understands english and/or spanish well enough to complete study assessment. exclusion criteria: * two exceptions: (1) children with special needs that preclude engagement in a nutrition-based behavioral intervention (e.g., g-tube dependence) and (2) children who are in state custody.

Keywords: hybrid design implementation effectiveness parent training cost-effectiveness primary care integrated behavioral health family-based prevention family check-up 4 health fidelity
the role of echocardiographic contrast (optison) in enhancing tricuspid regurgitation spectral doppler signals

Conditions: Hypertension, Pulmonary

Summary: the investigators aim to correlate noninvasive pulmonary artery systolic pressure (pasp) measurements obtained with and without echocardiographic contrast (optison) during transthoracic echocardiography (tte) with those obtained invasively and simultaneously during right heart catheterization, as the gold standard.

in the united states, pulmonary hypertension (pht) is an increasingly recognized cause of morbidity and mortality. echocardiography, due to its widespread use, versatility, portability, noninvasive nature, and safety, is routinely used as the primary method for diagnosis and evaluation of these patients. however, in this very cohort, its accuracy is frequently compromised by poor acoustic windows. the use of echocardiographic contrast (ec) in such patients may increase diagnostic accuracy, eliminate the need for performing more invasive, time-consuming, and expensive tests, and eliminate potential diagnostic and management errors. pulmonary artery systolic pressure (pasp) is routinely measured noninvasively with transthoracic echocardiography (tte) by obtaining the tricuspid regurgitant velocity (trv) with continuous wave spectral doppler and applying the modified bernoulli equation. the investigators aim to use the fda approved perflutren-based ec agent optison to augment inadequate tr cw spectral doppler envelopes and determine if the trv and pasp measurements obtained with the use of optison correlate better with the invasive measurements obtained simultaneously during right heart catheterization as opposed to those measurements obtained without the use of ec.

Eligibility criteria:
inclusion criteria: * consecutive patients (age ≥ 18 years old) undergoing right heart catheterization catheterization laboratory for various clinical indications as part of routine medical care; * only patients with poor acoustic windows will be included (based on previous studies, body habitus); exclusion criteria: * atrial fibrillation or other irregular rhythms (bigeminy, frequent ectopy) * pregnant women * known allergy to perflutren, blood products, albumin * patients who cannot receive blood products due to religious beliefs * evidence of intracardiac right to left shunting

Keywords: pulmonary artery systolic pressure optison
effects of vitamin d supplementation on muscle function among grave's disease patients

Conditions: Graves Disease

Summary: introduction: a deficit in vitamin d may be involved in the development and presentation of graves' disease (gd). lack of vitamin d and gd are linked to deteriorating quality of life (qol) and weakening of the muscles. our goal was to look at the possible advantages of vitamin d supplementation for the improvement of thyroid-related qol and muscle function in gd patients, as well as the possible drawbacks of anti-thyroid drugs (atd). methodology: a multicenter randomized controlled experiment with single-blinding was carried out with 48 patients who had been diagnosed with graves' illness. the participants were split into two groups n=24 patients in each group. in addition to standard atd, group a received either 70 μg (2800 iu) of vitamin d daily or a corresponding placebo. investigator measured muscular function and isometric strength at baseline, three, and nine months.


Eligibility criteria:
inclusion criteria: * grave's disease * either starting or about to start anti-thyroid medication (atd) exclusion criteria: * chronic granulomatous disease * hypercalcemia * poor renal function (egfr \< 45 ml/min) * the presence of malignant disease
quality of life assessment of chronic pancreatitis endoscopic interventions

Conditions: Chronic Pancreatitis

Summary: this study seeks to evaluate the effect of endoscopic interventions on quality of life in patients with chronic pancreatitis. quality of life will be evaluated using the panqoli, a validated quality of life instrument specific to chronic pancreatitis. endoscopic interventions will include pancreatic duct dilation and stenting, celiac plexus block, lithotripsy and removal of pancreatic duct stones, and pseudocyst drainage.

this is a multicenter prospective cohort study assessing the impact of endoscopic interventions on patients with chronic pancreatitis. patients with chronic pancreatitis referred for endoscopic treatment, including pancreatic duct dilation and stenting, pseudocyst drainage, celiac plexus blocks, and pseudocyst drainage/necrosectomy will be enrolled in this study. they will receive a baseline evaluation using the panqoli, a chronic pancreatitis-specific quality of life instrument, in addition to a visual analog scale to measure their pain. demographic and endoscopic features will be collected in addition to pain medication use. patients will receive follow-up at 1, 3, and 6 months post-intervention consisting of the panqoli, visual analog scale for pain, and pain medication use.

Eligibility criteria:
inclusion criteria: * patients with painful chronic pancreatitis, defined as either 1) the presence of pancreatic calcifications on cross-sectional imaging, 2) morphologic changes consistent with the rosemont criteria on endoscopic ultrasound, or 3) endoscopic pancreatic function test results consistent with decreased pancreatic function. exclusion criteria: * pregnant females * prisoners * patients under the age of 18 * patients lacking the capacity to consent

Keywords: chronic pancreatitis quality of life
effect of choline alphoscerate on cognitive function in alzheimer's dementia

Conditions: Alzheimer's Disease

Summary: this study will evaluate the performance of alzheimer's disease assessment scale-cognitive subscale (adas-cog) in patients with alzheimer's disease (ad).


Eligibility criteria:
inclusion criteria: * 50 - 90 years of age * clinical diagnosis of dementia of the alzheimer type determined by diagnostic and statistical manual of mental disorders (dsm-iv) criteria * a diagnosis of probable alzheimer's disease, or mild to moderate ad determined by nia-aa (national institute on aging and the alzheimer's association) criteria * k-mmse score of 12 - 26 * global clinical dementia rating (cdr) score of 0.5 - 2 * patient taking 10 mg of donepezil per day for a minimum of 12 weeks with a stable dose, not taking other brain pills including choline alfoscerate for at least 2 weeks from screening. drugs that are likely to affect cognition are permissible if the dose is regular and stable for at least 2 weeks before screening and if the treatment continues for the duration of the trial. exclusion criteria: * subject suspected of dementia due to organic causes other than alzheimer's type dementia * other degenerative brain diseases or major mental illnesses such as major depression, bipolar disorder, alcohol/substance abuse or dependence, delirium * hypersensitive to choline alfoscerate, donepezil hydrochloride, or piperidine derivatives or the components of this drug * subject who has contraindications as listed in the spc of choline alfoscerate or donepezil hydrochloride * other than the above who is deemed to be ineligible to participate in the trial
effect of a gnrh injection on ghrelin concentrations in girls with suspected premature puberty

Conditions: Puberty, Precocious

Summary: the purposes of the study is to investigate whether circulating levels of ghrelin decreases after an iv injection of gnrh in girls with suspected central premature puberty and to investigate the effects of different post sampling handling on the preservation of acylated ghrelin.

patients with clinically suspected central premature puberty undergo a gnrh stimulation test to have an appropriate diagnosis. 20 such girls will be recruited to this study and a modified gnrh stimulation test will be done. the modification includes prolonged blood sampling time (0, 30, 60, 90, 120, and 150 min after the gnrh injection instead of the usual 0, 30, 60, and 90 min). the girls will also be investigated twice. in randomised order they will be given either gnrh or placebo (isotone saline), on different days. one week to one month will separate the different investigation days. the proteinase inhibitor 4-(2-aminoethyl) benzene-sulfonyl fluoride hydrochlorid (aebsf) will be added to some of the blood tubes, and hydrochloric acid will be added to some of the plasma. all plasma samples will be frozen and all analyses will be done at the same time. acylated ghrelin will be analyzed by millipore's specific elisa kit and deacylated ghrelin will be analyzed by cayman's specific elisa kit. anthropometric data as well as pubertal state will be collected. p-glucose, s-insulin, s-follicle stimulating hormone (fsh), s-luteinizing hormone (lh), and s-estradiol will also be analyzed.

Eligibility criteria:
inclusion criteria: * female gender. * clinical suspicion of central precocious puberty. * a gnrh stimulation test is to be performed to make appropriate diagnosis. exclusion criteria: * age \< 1 year. * weight \< 10 kg. * untreated hypo- or hyperthyroidism. * diabetes of any kind. * bmi \> 3 z-score. * growth hormone treatment. * syndrome or suspected syndrome. * tumour or congenital malformation of the hypothalamus or the pituitary gland. (neuroradiology does not have to be performed only because of the study.) * on going ulcus ventriculi or the patient has gone through surgery that removed part of the ventricle or changed it markedly in any other way.

Keywords: females ghrelin gnrh randomized, controlled study children
effects of exercise therapy adjuvant device on head and neck cancer patients in the treatment of cancer therapy induced trismus

Conditions: Maximum Interincisal Opening

Summary: trismus is traditionally considered being a late effect of cancer therapy with functional deficits becoming clear in the first year after completing radiation therapy. these deficits can rapidly progress to a state of functional impairment. the most common treatment for trismus is physical therapy comprising an active range of motion (rom) exercises, hold and relax techniques. once trismus has developed, it may be hard to reverse. thus, prevention with a program of self-care is important for managing this side effect. this study want to test the effect with adjunctive devices plus exercise to prevent trismus.


Eligibility criteria:
inclusion criteria: 1. age is greater than or equal to 20 years old. 2. those who are able to communicate in mandarin and taiwanese and have no reading or listening or writing disabilities can fill out the questionnaire by themselves or with the assistance of the researcher. 3. diagnosed with head and neck cancer, and is expected to receive head and neck radiation therapy for the first time. 4. a clear consciousness, no severe cognitive impairment or mental symptoms. 5. willing to participate in this research and obtain consent. exclusion criteria: 1. people with known temporomandibular joint disorders. 2. the maximum opening degree is less than or equal to 25 mm. 3. those who have received radiotherapy for the head and neck in the past. 4. those who have been diagnosed by a physician for poor wound healing after surgery and unable to perform mouth-opening rehabilitation exercises.

Keywords: trismus head and neck cancer radiotherapy maximum interincisal opening
study of t-dxd monotherapy in patients with her2-expressing locally advanced or metastatic gastric or gej adenocarcinoma who have received 2 or more prior regimens

Conditions: Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Summary: this is a phase ii, open-label, single-arm, multicentre, study in china assessing the efficacy and safety of t-dxd in participants with her2-expressing advanced gastric or gej adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent


Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 years of age 2. pathologically documented gastric or gej adenocarcinoma 3. disease progression on or after ≥ 2 prior platinum and fluoropyrimidine agents for advanced/metastatic disease 4. ecog ps 0-1 5. willing and able to provide an adequate newly-acquired tumour sample for confirmation of her2 status 6. lvef ≥ 50% exclusion criteria: 1. pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or cell-free and cart. drainage and cart. 2. spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids 3. active primary immunodeficiency, known hiv, active hbv, hcv infection. 4. uncontrolled infection requiring iv antibiotics, antivirals, or antifungals. 5. history of non-infectious pneumonitis/ild, current ild, or where suspected ild that cannot be ruled out by imaging at screening. 6. lung-specific intercurrent clinically significant severe illnesses.

Keywords: gastric cancer gastroesophageal junction adenocarcinoma her2 trastuzumab deruxtecan t-dxd ds-8201a erbb2
identification of biomarkers in women at high risk or average risk of breast cancer

Conditions: Breast Cancer

Summary: rationale: collecting and storing samples of blood and studying them in the laboratory may help doctors learn more about changes that may occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is examining biomarkers in women with a high risk or average risk of breast cancer.

objectives: primary * identify and validate serum biomarkers that can distinguish malignant from benign and normal breast conditions in women at high risk or average risk for breast cancer. secondary * standardize procedures for recruitment, characterization, and follow-up of participants and collection, processing, storage, and analysis of specimens. * assess marker variability over time in healthy controls. * develop a shared specimen resource to support ongoing early detection research. outline: blood samples are collected every 6 months and assayed for the presence of biomarkers. projected accrual: a total of 625 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * planning to undergo outpatient annual mammogram or biopsy and meets 1 of the following criteria: * high risk for breast cancer * high risk with newly-diagnosed\* breast cancer * average risk for breast cancer * average risk with newly-diagnosed\* breast cancer * benign breast disease note: \* diagnosed at time of study enrollment * no other breast cancer diagnosis within the past year * hormone receptor status: * not specified patient characteristics: age * 25 and over sex * female menopausal status * not specified performance status * not specified life expectancy * not specified hematopoietic * no hemophilia * no other bleeding disorders hepatic * not specified renal * not specified other * not pregnant or nursing * at least 6 months postpartum * no planned pregnancy within the next year * no history of medical conditions that would increase participant risk of blood draws * no psychiatric, psychological, or other condition that would preclude giving informed consent prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * no prior double mastectomy other * no concurrent treatment for breast cancer

Keywords: breast cancer stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer